

Remarks

In the Office Action dated July 6, 2007, claims 21, 25, 38 and 42 were withdrawn and claims 20, 22-24, 26-30, 32-34, 36, 37, 39-41 and 43-50 were rejected. Applicants are using what is believed to be the Examiner's numbering system in the amendment *supra* and the remarks *infra*.

Applicant has carefully reviewed the Office Action and provide the amendments above and the remarks to follow as a full and complete response thereto.

Applicant has amended paragraphs [0055], [0057] and [0073] to conform to the Examiner's suggestions.

With regard to line 1 of page 25 applicants are submitting the requested line 1, page 25, for the third time.

Applicant has cancelled claims 1 through 35 and noted the withdrawal of claims 38 and 42. Claims 36-37, 39-41 and 43-50 are submitted for reconsideration. The dependencies have been adjusted to the new numbering system and those changes are noted as amendments. The claims now pending are those allowed by the European Patent Office.

All claims pending have been rejected over Kratz et al. J. Med. Chem. 43, 1253 (2000), Applicants' own paper. Attached is a verified translation of the priority document, DE 188 26 475.9, filed June 10 1999. Submission of this translation perfects Applicants' claim to priority and overcomes the stated rejection.

All issues having been addressed and corrected, Applicant submits that this application is in condition for allowance and requests reconsideration and favorable action thereon.

Respectfully submitted,

J. Herbart

J. Herbert O'Toole  
Registration No. 31,404  
Attorney for Applicant  
NEXSEN PRUET, LLC  
P.O. Box 10107  
Greenville, SC 29603  
Telephone: 864/370-2211  
Facsimile: 864/282-1177

Attachments: Verified Translation of Priority Document No. DE 199 26 475.9